News Vtesse's rare disease drug set for UK early access Vtesse drug "promising" treatment for NPC disease, says regulator.
News US advisers back Cempra pneumonia antibiotic But panel of FDA advisers concerned over liver safety.
News UK blood cancer patients get early access to BMS drug Nivolumab made available ahead of EU approval in relapsed cHL.
News Academia, not pharma, worse at publishing trial findings Shire and BMS hailed as clinical trial transparency champions.
News Novartis' LEE011 on fast track to challenge Ibrance US regulator grants fast review for breast cancer drug.
News Gilead strikes again, penning $5bn deal to buy Tubulis Gilead has signed its third acquisition deal since the start of the year, agreeing to buy ADC specialist Tubulis for $3.15bn upfront.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
